✨
AI Summary
- Novo Nordisk faces challenges due to a missed Alzheimer's drug opportunity.
- Eli Lilly's innovation and management give it an edge over Novo Nordisk.
- Novo Nordisk's stock drop is not seen as a buying opportunity.
More from Earn Your Leisure
